A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Rapastinel adjunctive to antidepressant therapy in patients with major depressive disorder who have a partial response to antidepressant therapy.

The method used for this study is a randomized, double-blind, placebo-controlled, parallel-group, 3-week study in patients with major depressive disorder who have a partial response to ongoing antidepressant therapy.

Study phase: III

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

Male and female outpatients who are 18 to 65 years of age.
Have no more than partial response (<50% improvement) to ongoing treatment with a protocol-allowed antidepressant therapy.

Please contact the study coordinator for additional eligibility and study related information.

Primary disease category: Mental Health

Sponsor: ALLERGAN SALES, LLC

Projected enrollment dates: November 2016 to September 2018

Official study title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder